Coverage-gated living condition brief

Diabetes Mellitus, Type 2 peptide evidence brief

A cited Diabetes Mellitus, Type 2 peptide evidence brief across 33 exact-label ClinicalTrials.gov records, 11 connected profiles, and 8 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

33 selected records.

Connected peptides

11 profiles.

Registry update years

2014–2026 in selected records.

Direct collection answer · published August 17, 2026

What peptide evidence does PeptideScanner carry for Diabetes Mellitus, Type 2?

PeptideScanner’s selected collection contains 33 retained ClinicalTrials.gov records carrying the exact condition label “Diabetes Mellitus, Type 2,” connected to 11 peptide profiles across 8 registry-update years.

That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Diabetes Mellitus, Type 2, and it is not a safety or efficacy assessment.

Indication intelligence

Selected evidence landscape

Trial phases4

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses4

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 348 selected PubMed records and 28 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Diabetes Mellitus, Type 2 unless their own cited source says so.

Related profile context

Literature connected through these peptide profiles

All literature facets →

This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Diabetes Mellitus, Type 2.

Albiglutide · source record 2021-02-01

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.

PubMed lists PMID 32219329 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2020-06-01 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Eloralintide · source record 2026-08-15

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

PubMed lists PMID 41559929 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Multicenter Study, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug eloralintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Dulaglutide · source record 2026-01-27

Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.

PubMed lists PMID 29094890 in American family physician as Journal Article, with publication-date metadata of 2017-10-15 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Efinopegdutide · source record 2026-11-09

Efinopegdutide: a step towards precision in MASH therapy?

PubMed lists PMID 43003104 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug efinopegdutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT00838903

PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 9, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00838916

PeptideScanner retained ClinicalTrials.gov record NCT00838916 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 9, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00839527

PeptideScanner retained ClinicalTrials.gov record NCT00839527 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 9, 2017
Evidence lane
Clinical trials

Exact-record source chronology

Diabetes Mellitus, Type 2 registry timeline

All trial facets →

Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.

2026

15 records

2025

1 record

2023

1 record

2020

1 record

2019

1 record

2018

1 record

2017

12 records

2014

1 record
What this brief cannot answer